Abstract
Background: Patients with atopic dermatitis (AD) suffer from a multidimensional disease burden. We report clinically meaningful improvements in AD signs, symptoms, and quality of life in children treated with FDA-approved doses of dupilumab.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have